Revvity Q1 2026 earnings snapshot

Revvity (RVTY) has just put fresh numbers on the table, with recent quarters showing revenue between US$664.8 million and US$772.1 million and basic EPS ranging from US$0.35 to US$0.85 as the company heads into its Q1 2026 update. Over the past year, revenue has been recorded from US$684.0 million in Q3 2024 up to US$772.1 million in Q4 2025, while basic EPS prints in that stretch run from US$0.35 to US$0.85, giving investors a clear view of how the top line and EPS have moved quarter to quarter. With trailing 12 month net profit margin at 8.4% compared with 10.3% a year earlier and a large one off loss affecting recent earnings, the focus now is on how investors weigh near term growth expectations against pressure on margins.

See our full analysis for Revvity.

With the headline figures in place, the next step is to see how these results line up with the stories you hear most often about Revvity, and where the numbers push back against those narratives.

TTM revenue at US$2.9b with steady quarterly run rate

• On a trailing 12 month basis, Revvity booked US$2.9b of revenue, with recent quarters ranging from US$664.8 million to US$772.1 million. The business is running at a fairly consistent top line even as growth is measured at 6.4% per year versus a US market comparator of 11.2% per year.
• Consensus narrative sees this slower 6.4% revenue growth as enough to support future earnings, yet the multi year 40.4% annual decline in trailing earnings shows that top line momentum alone has not turned into durable profit growth.
  • On the one hand, analysts expect earnings to grow about 21.1% per year over the next three years, pointing to a different earnings path ahead than the past five year decline suggests.
  • On the other hand, trailing 12 month net income of US$239.9 million is below the US$296.0 million level seen in the earlier trailing period, which keeps the recent track record firmly on the cautious side of that story.

Margins pressured at 8.4% as one off loss bites

• Net profit margin sits at 8.4% on the latest trailing 12 month numbers compared with 10.3% a year earlier. That gap also reflects a US$91.3 million one off loss that weighs on how clean those earnings look.
• Bears argue that weaker profitability and policy risks in diagnostics could limit any margin recovery, and the current margin profile gives some support to that view.
  • Regulatory changes in China are tied to high teen declines in parts of the immunodiagnostics business, which fits with the picture of pressure on high margin diagnostic revenue rather than broad based expansion.
  • At the same time, management actions aimed at lifting operating margins above 28% rely on executing cost programs while dealing with tariffs and funding constraints. The move from a 10.3% to 8.4% net margin shows that margin improvement is not yet visible in the trailing data.

Skeptics highlight how much of the recent margin story hangs on cost actions in diagnostics and life sciences, so it can be useful to see how a bearish narrative frames those execution and policy risks over the next few years 🐻 Revvity Bear Case.

Valuation gap vs DCF and 113.36 price target

• At a share price of US$92.30, Revvity is presented as trading below a DCF fair value of about US$142.27 and below an analyst price target of US$113.36. Trailing earnings of US$239.9 million imply a P/E that the analysis notes is above the broader Global Life Sciences industry average of 36.5x but below a 77.6x peer average.
• Bullish investors point to this gap between price, DCF fair value and targets as a potential upside case, yet the earnings track record and current P/E keep the story more balanced than a simple discount might suggest.
  • The DCF fair value of roughly US$142.27 and the 113.36 target both sit well ahead of the current US$92.30 price, which aligns with the view that the stock price does not fully reflect forecast earnings growth of about 21.1% per year.
  • However, a 40.4% annual decline in trailing earnings over five years and an 8.4% net margin that is below last year mean the higher than industry P/E still rests on forecasts rather than recent profitability.

Bulls often focus on that discount to DCF fair value and analyst targets, so if you want to see how that upside case is built from growth and margin assumptions, it is worth reading the fuller bullish narrative 🐂 Revvity Bull Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Revvity on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of risks and potential rewards here feels finely balanced, it is worth checking the numbers yourself and deciding how comfortable you are with that trade off. To see that balance set out in one place and pressure test your own thesis, start with the 3 key rewards and 1 important warning sign.

Explore Alternatives

Revvity is working through weaker margins, a multi year 40.4% annual decline in trailing earnings and a P/E above the broader industry, all backed by forecasts that still need proving.

If that earnings and margin uncertainty feels like a lot to absorb, it can be worth shifting your attention to companies that already show stronger fundamentals via the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.